• 1. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Recent Advances in the Application of (5-Fluoro-1H-indazol-3-yl)methanol (CAS: 518990-02-8) in Chemical Biology and Pharmaceutical Research

The compound (5-Fluoro-1H-indazol-3-yl)methanol (CAS: 518990-02-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic scaffold, characterized by the presence of a fluorine atom and a hydroxymethyl group, serves as a key intermediate in the synthesis of various biologically active molecules. Recent studies have highlighted its potential in the design of kinase inhibitors, anticancer agents, and anti-inflammatory compounds, making it a focal point for medicinal chemists and researchers.

A study published in the Journal of Medicinal Chemistry (2023) demonstrated the efficacy of (5-Fluoro-1H-indazol-3-yl)methanol derivatives as selective inhibitors of cyclin-dependent kinases (CDKs), which play a critical role in cell cycle regulation. The researchers employed structure-activity relationship (SAR) analysis to optimize the scaffold, resulting in compounds with enhanced potency and selectivity. The lead compound, derived from this scaffold, exhibited nanomolar inhibitory activity against CDK4/6, with promising results in preclinical models of breast cancer.

In addition to its applications in oncology, (5-Fluoro-1H-indazol-3-yl)methanol has been explored for its potential in treating inflammatory diseases. A recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the synthesis of novel indazole-based compounds using this scaffold, which showed potent inhibition of interleukin-1β (IL-1β) production. The study emphasized the importance of the fluorine substitution in enhancing the metabolic stability and bioavailability of the compounds, paving the way for further development as anti-inflammatory therapeutics.

The synthetic versatility of (5-Fluoro-1H-indazol-3-yl)methanol has also been leveraged in the development of radiopharmaceuticals. A research group at the University of California, San Francisco, utilized this scaffold to design fluorine-18 labeled probes for positron emission tomography (PET) imaging. The probes demonstrated high target specificity and favorable pharmacokinetic properties, highlighting the scaffold's utility in diagnostic applications.

Despite these advancements, challenges remain in the optimization of (5-Fluoro-1H-indazol-3-yl)methanol derivatives for clinical use. Issues such as off-target effects, metabolic stability, and formulation need to be addressed through further research. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and translate these findings into viable therapeutic options.

In conclusion, (5-Fluoro-1H-indazol-3-yl)methanol (CAS: 518990-02-8) represents a promising scaffold in chemical biology and pharmaceutical research. Its applications span across multiple therapeutic areas, including oncology, inflammation, and diagnostics. Continued exploration of its derivatives and their mechanisms of action will undoubtedly yield novel insights and contribute to the development of next-generation therapeutics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)